LV5824A4 - Cilveku psihozes arstesanas panemiens - Google Patents

Cilveku psihozes arstesanas panemiens

Info

Publication number
LV5824A4
LV5824A4 LV960117A LV960117A LV5824A4 LV 5824 A4 LV5824 A4 LV 5824A4 LV 960117 A LV960117 A LV 960117A LV 960117 A LV960117 A LV 960117A LV 5824 A4 LV5824 A4 LV 5824A4
Authority
LV
Latvia
Prior art keywords
people
psychiatric treatment
psychiatric
treatment
Prior art date
Application number
LV960117A
Other languages
English (en)
Other versions
LV5824B4 (lv
Inventor
Jens Kristian Perregaard
Torben Skarsfeldt
Original Assignee
Lundbeck & Co As H
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB898908085A external-priority patent/GB8908085D0/en
Application filed by Lundbeck & Co As H filed Critical Lundbeck & Co As H
Publication of LV5824A4 publication Critical patent/LV5824A4/lv
Publication of LV5824B4 publication Critical patent/LV5824B4/lv

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
LV960117A 1989-04-11 1996-04-16 Cilveku psihozes arstesanas panemiens LV5824B4 (lv)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB898908085A GB8908085D0 (en) 1989-04-11 1989-04-11 New therapeutic use
US07/508,240 US5112838A (en) 1989-04-11 1990-04-11 Method of treating psychoses in human beings with the atypical neuroleptic 5-chloro-1-(4-fluorophenyl)-3-(1-(2-(2-imidazolidinon-1-yl)ethyl-4-piperidyl)1h-indole
US07/876,040 US5238945A (en) 1989-04-11 1992-04-30 Method of treating psychoses

Publications (2)

Publication Number Publication Date
LV5824A4 true LV5824A4 (lv) 1997-10-20
LV5824B4 LV5824B4 (lv) 1998-08-20

Family

ID=27264408

Family Applications (1)

Application Number Title Priority Date Filing Date
LV960117A LV5824B4 (lv) 1989-04-11 1996-04-16 Cilveku psihozes arstesanas panemiens

Country Status (2)

Country Link
US (1) US5238945A (lv)
LV (1) LV5824B4 (lv)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2000507544A (ja) 1996-03-25 2000-06-20 イーライ・リリー・アンド・カンパニー 痛みの治療方法
US6489341B1 (en) 1999-06-02 2002-12-03 Sepracor Inc. Methods for the treatment of neuroleptic and related disorders using sertindole derivatives
ATE503845T1 (de) * 2001-12-10 2011-04-15 Novartis Pharma Gmbh Verfahren zur behandlung von psychosen und schizophrenie auf der basis eines polymorphismus im cntf gen
AU2004237951A1 (en) * 2003-05-16 2004-11-25 Pfizer Products Inc. Therapeutic combinations of atypical antipsychotics with GABA modulators, anticonvulsants or benzodiazapines
GB0326148D0 (en) 2003-11-10 2003-12-17 Lilly Co Eli Morpholine derivatives
EP1696857A2 (en) * 2003-12-04 2006-09-06 The Research Foundation Of the City university of New York Clozapine and cocaine effects on dopamine and serotonin release in nucleus accumbens during psychostimulant behavior and withdrawal
EP1737473A4 (en) * 2004-04-19 2009-08-26 Noven Therapeutics Llc COMBINATIONS OF LITHIUM AND USES THEREOF
BRPI0510942A (pt) * 2004-05-11 2007-07-17 Pfizer Prod Inc combinação de antipsicóticos atìpicos e antagonistas do receptor 5-ht1b
MY147767A (en) * 2004-06-16 2013-01-31 Janssen Pharmaceutica Nv Novel sulfamate and sulfamide derivatives useful for the treatment of epilepsy and related disorders
TW200612905A (en) * 2004-06-16 2006-05-01 Janssen Pharmaceutica Nv Novel sulfamate and sulfamide derivatives useful for the treatment of epilepsy and related disorders
TW200616608A (en) * 2004-07-09 2006-06-01 Forest Laboratories Memantine as adjunctive treatment to atypical antipsychotics in schizophrenia patients
MX2007002309A (es) * 2004-08-24 2007-10-08 Johnson & Johnson Novedosos derivados de heteroarilsulfamida benzofusionados utiles como agentes anticonvulsivos.
JP2008545650A (ja) * 2005-05-20 2008-12-18 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ スルファミド誘導体の製造方法
US20070212412A1 (en) * 2005-09-08 2007-09-13 H. Lundbeck A/S Stable solid formulation of sertindole
US8937096B2 (en) * 2005-12-19 2015-01-20 Janssen Pharmaceutica Nv Use of benzo-fused heterocyle sulfamide derivatives for the treatment of mania and bipolar disorder
US8691867B2 (en) * 2005-12-19 2014-04-08 Janssen Pharmaceutica Nv Use of benzo-fused heterocycle sulfamide derivatives for the treatment of substance abuse and addiction
US8492431B2 (en) * 2005-12-19 2013-07-23 Janssen Pharmaceutica, N.V. Use of benzo-fused heterocycle sulfamide derivatives for the treatment of obesity
US8497298B2 (en) * 2005-12-19 2013-07-30 Janssen Pharmaceutica Nv Use of benzo-fused heterocycle sulfamide derivatives for lowering lipids and lowering blood glucose levels
US20070155827A1 (en) * 2005-12-19 2007-07-05 Smith-Swintosky Virginia L Use of benzo-fused heterocycle sulfamide derivatives for the treatment of depression
US20070155823A1 (en) * 2005-12-19 2007-07-05 Smith-Swintosky Virginia L Use of benzo-fused heterocycle sulfamide derivatives as neuroprotective agents
US8716231B2 (en) 2005-12-19 2014-05-06 Janssen Pharmaceutica Nv Use of benzo-fused heterocycle sulfamide derivatives for the treatment of pain
EP2026790A2 (en) * 2006-05-19 2009-02-25 Janssen Pharmaceutica, N.V. Co-therapy for the treatment of epilepsy and related disorders
TW200821296A (en) * 2006-06-01 2008-05-16 Lundbeck & Co As H Use of sertindole for the preventive treatment of suicidal behaviour
EP2041304B1 (en) 2006-06-12 2011-09-07 Hadasit Medical Research Services & Development Limited Rgs2 genotypes associated with extrapyramidal symptoms induced by antipsychotic medication
JP2010510314A (ja) 2006-11-22 2010-04-02 シーサイド セラピューティクス，エルエルシー 精神遅滞、ダウン症候群、脆弱ｘ症候群および自閉症の治療方法
US20090247617A1 (en) * 2008-03-26 2009-10-01 Abdel-Magid Ahmed F Process for the preparation of benzo-fused heteroaryl sulfamates
EP2288345B1 (en) 2008-04-18 2015-06-10 University College Dublin National University Of Ireland, Dublin Psycho-pharmaceuticals
EA018567B1 (ru) * 2008-06-23 2013-08-30 Янссен Фармацевтика Нв Кристаллическая форма (2s)-(-)-n-(6-хлор-2,3-дигидробензо[1,4]диоксин-2-илметил)сульфамида
EP2321011A1 (en) * 2008-06-25 2011-05-18 Pfizer Inc. Diaryl compounds and uses thereof
US8815939B2 (en) * 2008-07-22 2014-08-26 Janssen Pharmaceutica Nv Substituted sulfamide derivatives
US8252801B1 (en) 2009-06-03 2012-08-28 Abbott Laboratories Treatment of schizophrenia and related disorders
JP6440625B2 (ja) 2012-11-14 2018-12-19 ザ・ジョンズ・ホプキンス・ユニバーシティー 精神分裂病を処置するための方法および組成物
WO2014144663A1 (en) 2013-03-15 2014-09-18 The Johns Hopkins University Methods and compositions for improving cognitive function
CA2904767C (en) 2013-03-15 2022-06-21 Agenebio, Inc. Methods and compositions for improving cognitive function
US10925834B2 (en) 2015-05-22 2021-02-23 Agenebio, Inc. Extended release pharmaceutical compositions of levetiracetam

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4359468A (en) * 1981-02-25 1982-11-16 Boehringer Ingelheim Ltd. Antiallergic N-[4-(indolyl)-piperidino-alkyl]-benzimidazolones
IE58370B1 (en) * 1985-04-10 1993-09-08 Lundbeck & Co As H Indole derivatives
US4742057A (en) * 1985-12-05 1988-05-03 Fujisawa Pharmaceutical Co., Ltd. Antiallergic thiazole compounds
GB8908085D0 (en) * 1989-04-11 1989-05-24 Lundbeck & Co As H New therapeutic use

Also Published As

Publication number Publication date
LV5824B4 (lv) 1998-08-20
US5238945A (en) 1993-08-24

Similar Documents

Publication Publication Date Title
LV5824B4 (lv) Cilveku psihozes arstesanas panemiens
NO179531C (no) Fremgangsmåte for brönnbehandling
DK373688D0 (da) Behandlingsmetode
MX9102079A (es) Plemezcla de semduramicina
KR900015532U (ko) 일부인
ITMI912654A1 (it) Combinazione di estrusore-calandra
KR900015343U (ko) 안마겸용 때밀이 장치
GB9022470D0 (en) Treatment of clays
KR900016687U (ko) 안마구
IT8922217A0 (it) Massaggiatore
MX9202678A (es) Factores estimulantes de megacariocito
LT2311B (lt) Odos melanomos gydimo budas
KR890012669U (ko) 지압악력기
KR900014255U (ko) 안마구
KR920004003U (ko) 지압 겸용 안마기
ES1011087Y (es) Banera de hidromasaje
KR900019989U (ko) 지압 완력기
KR930026760U (ko) Tvcr의 개선된 구성
KR910004016U (ko) 지압구
KR910008644U (ko) 지압기
KR910000305U (ko) 지압구
CS136289A1 (en) Treatment of bottomsfrom cyclohexanone
SE8903088D0 (sv) Behandlingsstol
BR6901688U (pt) Massagiador terapeutico
SE9004160D0 (sv) Method of treating pain